कंपनी का अवलोकन
BioHarvest Sciences Inc. operates as a biotechnology firm with a primary footprint in Israel and the United States, utilizing a specialized botanical synthesis platform technology to cultivate plant cells that exhibit higher concentrations of active ingredients compared to traditional methods. The company functions within the Consumer Defensive sector, specifically targeting the Packaged Foods industry, a classification that suggests its products serve essential consumer needs regardless of economic cycles. This entity employs a workforce of 89 individuals and holds a total market capitalization of $97.02M, reflecting a small-cap status that indicates a relatively lower valuation compared to large-cap peers. The annual revenue recorded over the trailing twelve months stands at $34.51M, a figure that, when juxtaposed against the market cap, reveals the company is currently trading at a significant premium to its sales base, a characteristic often seen in biotechnology firms with high growth potential but尚未 realized profitability.
वित्तीय स्वास्थ्य
The financial performance metrics for BioHarvest Sciences Inc. show a revenue of $34.51M for the trailing twelve months, contrasted sharply by a net income loss of $11,135,000 and an EBITDA figure of $-5,111,000. The substantial gap between the positive revenue and the negative net income highlights a heavy cost structure where expenses, likely driven by research and development or operational overhead, consume the majority of gross earnings before reaching the bottom line. The company's free cash flow stands at $-10,782,250, which indicates a current lack of financial flexibility as the business is burning cash rather than generating liquidity from its operations. Despite these negative cash flows, the balance sheet holds $23.04M in cash against $14.10M in debt, resulting in a debt-to-equity ratio of 55.42, which suggests a leveraged position where the company relies significantly on equity financing relative to its obligations. Liquidity is further supported by a current ratio of 3.97, a metric that indicates the company possesses ample current assets to cover its short-term liabilities, providing a buffer for operational continuity. However, the return metrics present a challenging picture, with a return on equity of -83.2% and a return on assets of -9.6%, revealing that management has not yet generated positive returns on the capital invested or the assets utilized in the business model.
मूल्यांकन आकलन
Valuation multiples for BioHarvest Sciences Inc. present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive earnings and a forward P/E of -107.00, implying that the market expects earnings to remain negative in the near term or that valuation is being driven by non-earnings factors. The price-to-book ratio is calculated at 3.81, indicating that the stock trades at a substantial premium of nearly four times its tangible book value, which often reflects market expectations of future growth or intangible asset value in the biotech sector. Alternative valuation metrics such as the price-to-sales ratio of 2.81 and the EV/EBITDA of -17.23 suggest that investors are pricing the company based on sales growth rather than current profitability, a common practice for pre-revenue or loss-making biotechnology entities. The stock's price volatility is evident in its trading range, with a 52-week high of $12.80 and a 52-week low of $4.10, and the current price sits somewhere within this range, exhibiting a beta of 1.40. This beta value signifies that the stock is approximately 40% more volatile than the broader market, meaning price movements will likely amplify during market swings.
Growth & Income
The company demonstrates a robust revenue growth rate of 24.6% year-over-year, while earnings growth is listed as N/A due to the persistent net losses, indicating that top-line expansion is currently the primary driver of value rather than earnings expansion. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning that all generated cash flow is reinvested back into the business operations rather than distributed to shareholders. This reinvestment strategy is typical for growth-stage biotechnology companies that prioritize funding their botanical synthesis platforms and product development over providing income to investors. Overall, the growth and income profile of BioHarvest Sciences Inc. is characterized by high revenue expansion without current profit generation or dividend distribution, positioning the stock as a pure-play growth vehicle dependent on future operational improvements to achieve profitability.